Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.73 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.73 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 1/20 | 0.73 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.73 |
| ▸ | TOP1 | P11387 | 17/20 | 0.61 |
| ▸ | GLA | P06280 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5547333 | 0.90 | HTT (0.75) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL27598514 | 0.90 | HTT (0.77) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL4410537 | 0.90 | HTT (0.77) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL6713165 | 0.89 | HTT (0.76) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL31091151 | 0.89 | HTT (0.76) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL8472836 | 0.87 | HTT (0.73) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL6848603 | 0.87 | HTT (0.74) | HTTABCC3ABCC4ACHEPTGS1 | |
| SCHEMBL23269835 | 0.87 | GLA (0.74) | HTTABCC4TOP1GLAALDH1A1 | |
| SCHEMBL3766910 | 0.87 | GLA (0.74) | HTTABCC4TOP1GLAALDH1A1 | |
| SCHEMBL16521887 | 0.87 | HTT (0.72) | HTTABCC3ABCC4ACHEPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0879236-B1 | DERIVATIVES OF CAMPTOTHECIN FOR USE IN TREATING CANCER | CHRISTUS STEHLIN FOUNDATION FO (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-1829880-A2 | Derivatives of camptothecin for use in treating cancer | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2004091621-A1 | ALTERNATING TREATMENT OF CANCER WITH TOPOISOMERASE I AND TOPOISOMERASE II INHIBITORS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6407118-B1 | ANTITUMOR AGENTS; SIDE EFFECT REDUCTION | THE STEHLIN FOUNDATION FOR CANCER RESEARCH | 2002-06-18 | — | — | US | disclosed |
| EP-1200068-A2 | LIPOSOMAL PRODRUGS COMPRISING DERIVATIVES OF CAMPTOTHECIN AND METHODS OF TREATING CANCER USING THESE PRODRUGS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2002-05-02 | — | — | EP | disclosed |
| US-6352996-B1 | ANTICARCINOGENIC AGENTS AND LIPOSOMES | THE STEHLIN FOUNDATION FOR CANCER RESEARCH | 2002-03-05 | — | — | US | disclosed |
| US-20010031761-A1 | Derivatives of camptothecin and methods of treating cancer using these derivatives | CAO ZHISONG (US) | 2001-10-18 | — | — | US | disclosed |
| US-6218399-B1 | MODIFYING THE 20 POSITION OF CAMPTOTHECIN TO FORM A COMPOUND WHICH IS LOW TOXICITY USED IN CANCER THERAPY | THE STEHLIN FOUNDATION FOR CANCER RESEARCH | 2001-04-17 | — | — | US | disclosed |
| WO-2001008663-A2 | LIPOSOMAL PRODRUGS COMPRISING DERIVATIVES OF CAMPTOTHECIN AND METHODS OF TREATING CANCER USING THESE PRODRUGS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2001-02-08 | — | — | WO | disclosed |
| US-6120793-A | TRANSDERMAL ADMINISTERING | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2000-09-19 | — | — | US | disclosed |
| US-6096336-A | ACTIVE COMPONENT AND A LIPOSOMAL DELIVERY SYSTEM | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0879236-A1 | DERIVATIVES OF CAMPTOTHECIN FOR USE IN TREATING CANCER | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 1998-11-25 | — | — | EP | disclosed |
| US-5731316-A | ANTITUMOR AGENTS | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 1998-03-24 | — | — | US | disclosed |
| WO-1997028165-A1 | DERIVATIVES OF CAMPTOTHECIN FOR USE IN TREATING CANCER | THE STEHLIN FOUNDATION FOR CANCER RESEARCH (US) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031761-A1 | Derivatives of camptothecin and methods of treating cancer using these derivatives | HCCS, TOP2A, CBR1 | HTT 4788/4885ABCC3 146/4885ABCC4 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.